Affiliation:
1. Department of Neurosurgery, 521 Norinco General Hospital , Xi’an , 710000 , China
Abstract
Abstract
The present study investigates the effect of nickel oxide nanoparticles (NiO-NPs) on C6 glioma cells and develops a method for preparing NiO. Plant-based materials (leaf extract) can produce NPs efficiently and economically. Therefore, we developed NiO-NPs from Terminalia chebula leaf extract to reduce C6 glioblastoma cell proliferation. The structural, optical, and antimicrobial properties of NiO-NPs were investigated. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays, Acridine orange/ethidium bromide dual staining, Hoechst 33342, and Rh123 staining were used to evaluate nuclear changes and mitochondrial membrane potential (MMP) in C6 glioblastoma cells. X-ray diffraction analyses revealed the cubic structures of the synthesized NiO-NPs, field emission scanning electron microscope analysis revealed polygonal NiO-NPs and an energy-dispersive X-ray spectrometer confirmed the high purity of the synthesized NiO-NPs. V. cholera, S. pneumonia, S. aureus, B. subtilis, P. aeruginosa, K. pneumonia, and C. albicans were sensitive to NiO-NPs. When NiO-NPs were applied at lower concentrations to rat glioblastoma C6 cells, they dose-dependently inhibited viability and induced apoptosis. Our findings show that NiO-NPs exhibit altered MMP and nuclear integrity. In this study, NiO-NPs were synthesized using T. chebula leaf extract, which has antiproliferative properties, and NiO-NPs increased cell cytotoxicity in C6 cells. Further exploration of NiO-NPs in glioblastoma animal models should be investigated.
Reference67 articles.
1. Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, et al. National comprehensive cancer network. Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep;11(9):1114–51. 10.6004/jnccn.2013.0132. PMID: 24029126; PMCID: PMC4124889.
2. Liu S, Zhao Q, Shi W, Zheng Z, Liu Z, Meng L, et al. Advances in radiotherapy and comprehensive treatment of high-grade glioma: Immunotherapy and tumor-treating fields. J Cancer. 2021 Jan;12(4):1094–104. 10.7150/jca.51107. PMID: 33442407; PMCID: PMC7797642.
3. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013 Nov;15(Suppl 2):ii1–56. 10.1093/neuonc/not151. Erratum in: Neuro Oncol. 2014 May;16(5):760. PMID: 24137015; PMCID: PMC3798196.
4. Jain KK. A critical overview of targeted therapies for glioblastoma. Front Oncol. 2018 Oct;8:419. 10.3389/fonc.2018.00419. PMID: 30374421; PMCID: PMC6196260.
5. Cruz JVR, Batista C, Afonso BH, Alexandre-Moreira MS, Dubois LG, Pontes B, et al. Obstacles to Glioblastoma Treatment Two Decades after Temozolomide. Cancers. 2022 Jun;14(13):3203. 10.3390/cancers14133203. PMID: 35804976; PMCID: PMC9265128.